Recombinant Human VEGF 121 (aa 207-327) Protein

Name: Recombinant Human VEGF 121 (aa 207-327) Protein
Brand: R&D Systems
SKU: 4644-VS
Rating: 4 (1 reviews)

Catalog #: 4644-VS
15 Citations 1 Review Datasheet / COA / SDS

Carrier Free

Catalog #	Availability	Size / Price	Qty
4644-VS-010/CF

With Carrier

Catalog #	Availability	Size / Price	Qty
4644-VS-010

Best Seller

R&D Systems Recombinant Proteins and Enzymes

1 Image

All VEGF Proteins and Enzymes

Product Details

Citations (15)

FAQs

Reviews (1)

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human VEGF 121 (aa 207-327) Protein Summary

Product Specifications

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

Activity

Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323. The ED₅₀ for this effect is 1.00-8.00 ng/mL.

Source

E. coli-derived human VEGF protein
Ala207-Arg327, with an N-terminal Met & Pro208-Arg327

Accession #

NP_001020541

N-terminal Sequence
Analysis

Met & Pro208

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

14 kDa (monomer)

Product Datasheets

4644-VS (with carrier)

Product Datasheet

COA

SDS

4644-VS/CF (carrier free)

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

4644-VS

Formulation	Lyophilized from a 0.2 μm filtered solution in HCl with BSA as a carrier protein.
Reconstitution	Reconstitute at 100 μg/mL in sterile 4 mM HCl.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

4644-VS/CF

Formulation	Lyophilized from a 0.2 μm filtered solution in HCl.
Reconstitution	Reconstitute at 100 μg/mL in sterile 4 mM HCl.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

Background: VEGF

Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (1-3). It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cysteine-knot structure (4). Humans express alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) in length (4). VEGF₁₆₅ appears to be the most abundant and potent isoform, followed by VEGF₁₂₁ and VEGF₁₈₉ (3, 4). VEGF₁₂₁ is the only form that lacks a basic heparin-binding region and is freely diffusible (4). Mouse embryos expressing only the corresponding isoform (VEGF₁₂₀) do not survive to term, and show defects in skeletogenesis (5). Human VEGF₁₂₁ shares 87% aa sequence identity with corresponding regions of mouse and rat, 93% with feline, equine and bovine, and 91%, 95% and 96% with ovine, canine and porcine VEGF, respectively. VEGF binds the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells (4). Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity (3, 4). VEGF₁₆₅ binds the semaphorin receptor, Neuropilin-1; VEGF₁₂₁ binding has also been reported (6). VEGF is required during embryogenesis to regulate the proliferation, migration, and survival of endothelial cells (3, 4). In adults, VEGF functions mainly in wound healing and the female reproductive cycle (3). Pathologically, it is involved in tumor angiogenesis and vascular leakage (7, 8). Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (9). VEGF is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, oncostatin M and TNF-alpha (3, 4, 10).

References

Leung, D.W. et al. (1989) Science 246:1306.
Keck, P.J. et al. (1989) Science 246:1309.
Byrne, A.M. et al. (2005) J. Cell. Mol. Med. 9:777.
Robinson, C.J. and S.E. Stringer (2001) J. Cell. Sci. 114:853.
Zelzer, E. et al. (2002) Development 129:1893.
Pan, Q. et al. (2007) J. Biol. Chem. 282:24049.
Weis, S.M. and D.A. Cheresh (2005) Nature 437:497.
Thurston, G. (2002) J. Anat. 200:575.
Carvalho, J.F. et al. (2007) J. Clin. Immunol. 27:246.
Angelo, L.S. and R. Kurzrock (2007) Clin. Cancer Res. 13:2825.

Long Name

Vascular Endothelial Growth Factor

Entrez Gene IDs

7422 (Human); 22339 (Mouse); 83785 (Rat); 281572 (Bovine); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)

Alternate Names

MVCD1; VAS; vascular endothelial growth factor A; Vascular permeability factor; Vasculotropin; VEGF; VEGFA; VEGF-A; VEGFMGC70609; VPF; VPFvascular endothelial growth factor

Related Research Areas

Citations for Recombinant Human VEGF 121 (aa 207-327) Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

15 Citations: Showing 1 - 10
Filter your results:

Filter by:

Assessment of mouse VEGF neutralization by ranibizumab and aflibercept
Authors: Y Ichiyama, R Matsumoto, S Obata, O Sawada, Y Saishin, M Kakinoki, T Sawada, M Ohji
PLoS ONE, 2022-12-21;17(12):e0278951.
Species: N/A
Sample Types: Recombinant Protein
Applications: Western Blot
CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance
Authors: S Ma, LS Mangala, W Hu, E Bayaktar, A Yokoi, W Hu, S Pradeep, S Lee, PD Piehowski, A Villar-Pra, SY Wu, MH McGuire, OD Lara, C Rodriguez-, CJ LaFargue, NB Jennings, KD Rodland, T Liu, V Kundra, PT Ram, S Ramakrishn, G Lopez-Bere, RL Coleman, AK Sood
Cell Reports, 2021-08-17;36(7):109549.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
VEGF counteracts amyloid-&beta-induced synaptic dysfunction
Authors: L Martin, P Bouvet, N Chounlamou, C Watrin, R Besançon, D Pinatel, D Meyronet, J Honnorat, A Buisson, PA Salin, C Meissirel
Cell Reports, 2021-05-11;35(6):109121.
Species: Human
Sample Types: Cell Culture Supernates, Whole Cells
Applications: Bioassay, ELISA Capture
Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic mice
Authors: F Njau, N Shushakova, H Schenk, VC Wulfmeyer, R Bollin, J Menne, H Haller
PLoS ONE, 2020-01-14;15(1):e0218494.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
VEGF-A-Cleavage by FSAP and Inhibition of Neo-Vascularization
Authors: Ö Uslu, J Herold, S M Kanse
Cells, 2019-11-06;8(11):.
Species: Human
Sample Types: Recombinant Protein
Applications: Bioassay
A VEGF-A/SOX2/SRSF2 network controls VEGFR1 pre-mRNA alternative splicing in lung carcinoma cells
Authors: C Abou Fayca, S Gazzeri, B Eymin
Sci Rep, 2019-01-23;9(1):336.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
Growth Factor-like Gene Regulation Is Separable from Survival and Maturation in Antibody-Secreting Cells
Authors: S Stephenson, MA Care, I Fan, A Zougman, DR Westhead, GM Doody, RM Tooze
J. Immunol., 2019-01-14;202(4):1287-1300.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using (111)In-bevacizumab
Authors: N Patel, S Able, D Allen, E Fokas, B Cornelisse, FV Gleeson, AL Harris, KA Vallis
EJNMMI Res, 2017-05-30;7(1):49.
Applications: Western Blot
Engineered ligand-based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis
Authors: S Kapur, AP Silverman, AZ Ye, N Papo, D Jindal, MS Blumenkran, JR Cochran
Bioeng Transl Med, 2017-02-17;2(1):81-91.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
Fluorescent resonance energy transfer imaging of VEGFR dimerization.
Authors: Ahmadova Z, Yagublu V, Forg T, Hajiyeva Y, Jesenofsky R, Hafner M, Keese M
Anticancer Res, 2014-05-01;34(5):2123-33.
Species: Hamster
Sample Types: Whole Cells
Applications: Bioassay

The docking protein FRS2alpha is a critical regulator of VEGF receptors signaling.
Authors: Chen P, Qin L, Zhuang Z, Tellides G, Lax I, Schlessinger J, Simons M
Proc Natl Acad Sci U S A, 2014-04-02;111(15):5514-9.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

Heparin binding VEGF isoforms attenuate hyperoxic embryonic lung growth retardation via a FLK1-neuropilin-1-PKC dependent pathway.
Authors: Esquibies A, Karihaloo A, Quaggin S, Bazzy-Asaad A, Cantley L
Respir Res, 2014-03-19;15(0):32.
Species: Mouse
Sample Types: Whole Tissue
Applications: Bioassay

Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-eclampsia: expression of Flt-1 and endoglin.
Authors: Tannetta D, Dragovic R, Gardiner C, Redman C, Sargent I
PLoS ONE, 2013-02-20;8(2):e56754.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain.
Authors: Martino MM, Hubbell JA
FASEB J., 2010-07-29;24(12):4711-21.
Species: Human
Sample Types: Recombinant Protein
Applications: Surface Plasmon Resonance

VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo.
Authors: Rennel ES, Varey AH, Churchill AJ, Wheatley ER, Stewart L, Mather S, Bates DO, Harper SJ
Br. J. Cancer, 2009-08-25;101(7):1183-93.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay